The short version of RP-HPLC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-09-12. Anything still debated is marked as such rather than presented as settled.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Rubidium is the 16th most abundant element in the earth's crust; however, it is quite rare. Some minerals found in North America, South Africa, Russia, and Canada contain rubidium. Some potassium minerals (lepidolites, biotites, feldspar, carnallite) contain it, together with caesium. Pollucite, carnallite, leucite, and lepidolite are all minerals that contain rubidium. As a by-product of lithium extraction, it is commercially obtained from lepidolite. Rubidium is also found in potassium rocks and brines, which is a commercial supply. The majority of rubidium is now obtained as a byproduct of refining lithium. Rubidium is used in vacuum tubes as a getter, a material that combines with and removes trace gases from vacuum tubes. For several years in the 1950s and 1960s, a by-product of the potassium production called Alkarb was a main source for rubidium. Alkarb contained 21% rubidium while the rest was potassium and a small fraction of caesium. Today the largest producers of caesium, for example the Tanco Mine in Manitoba, Canada, produce rubidium as by-product from pollucite. Today, a common method for separating rubidium from potassium and caesium is the fractional crystallisation of a rubidium and caesium alum (Cs, Rb)Al(SO4)2·12H2O, which yields pure rubidium alum after approximately 30 recrystallisations. The limited applications and the lack of a mineral rich in rubidium limit the production of rubidium compounds to 2 to 4 tonnes per year. Caesium, however, is not produced from the above reaction.
Distal axonopathy, is the result of interrupted function of the peripheral nerves. It is the most common response of neurons to metabolic or toxic disturbances, and may be caused by metabolic diseases such as diabetes, kidney failure, connective tissue disease, deficiency syndromes such as malnutrition and alcoholism, or the effects of toxins or drugs such as chemotherapy. They may be divided according to the type of axon affected (large-fiber, small-fiber, or both). The most distal portions of axons are usually the first to degenerate, and axonal atrophy advances slowly toward the nerve's cell body. However, if the cause is removed, then regeneration is possible, although the prognosis depends on the duration and severity of the original stimulus. People with distal axonopathies usually present with sensorimotor disturbances such as amyotrophic lateral sclerosis. Myelinopathy, is due to a loss of myelin or of the Schwann cells. This demyelination slows down or completely blocks the conduction of action potentials through the axon of the nerve cell (neurapraxia). The most common cause is acute inflammatory demyelinating polyneuropathy AIDP, the most common form of Guillain–Barré syndrome (although other causes include chronic inflammatory demyelinating polyneuropathy). Neuronopathy is the result of issues in the peripheral nervous system (PNS) neurons. They may be caused by motor neurone diseases, sensory neuronopathies, toxins, or autonomic dysfunction. Neurotoxins such as chemotherapy agents may cause neuronopathies.
== History == The term was first suggested in 1980, as connective tissue disease in patients whose features did not meet other classification criteria. In 1999, a study noted, "In recent years, there has been growing concern regarding the diagnosis of incomplete forms of the autoimmune diseases" and the first classification criteria were proposed in that year. Historically, the condition was sometimes called undifferentiated connective tissue syndrome, latent lupus, or incomplete lupus.
=== Other tumors === In a few people, acromegaly is caused by tumors of the pancreas, lungs, and adrenal glands. These tumors also lead to an excess of GH, either because they produce GH themselves or, more frequently, because they produce GHRH (growth hormone-releasing hormone), the hormone that stimulates the pituitary to make GH. When these nonpituitary tumors are surgically removed, GH levels fall and the symptoms of acromegaly improve.
Men with gynecomastia may appear anxious or stressed due to concerns about its appearance and the possibility of having breast cancer. Particular studies suggest that gynecomastia can lead to various psychological and social challenges, such as depression, anxiety and disordered eating.
Sources: en.wikipedia.org
=== After age 35 === After age 35, acquired coronary artery disease predominates (80%), and this is true regardless of the athlete's former level of fitness. Various performance-enhancing drugs can increase cardiac risk, though evidence has been inconclusive about their involvement in sudden cardiac deaths.
The female movement of the 1960s, combined with Title IX and the all around fitness revolution, gave birth to new alternative perspectives of feminine beauty that included an athletic physique of toned muscle. This athletic physique was found in various popular media outlets such as fashion magazines. Female bodybuilders changed the limits of traditional femininity as their bodies showed that muscles are not only just for men.
=== Availability === Gonadorelin is available widely throughout the world for veterinary use, including in the United States, Canada, the United Kingdom, Ireland, elsewhere throughout Europe, South Africa, Australia, New Zealand, Japan, Taiwan. However, gonadorelin is not available for clinical use in humans in the United States.
Mikania micrantha is a tropical plant in the family Asteraceae; known as bitter vine, climbing hemp vine, or American rope. It is also sometimes called mile-a-minute vine (a moniker also used for the unrelated Persicaria perfoliata). It is a vigorously growing perennial creeper that grows best in areas in high humidity, light and soil fertility, though it can adapt in less fertile soils. The featherlike seeds are dispersed by wind. A single stalk can produce between 20 and 40 thousand seeds a season. The species is native to the sub-tropical zones of North, Central, and South America.
Sources: en.wikipedia.org
The DLD homodimer functions as the E3 component of the pyruvate, α-ketoglutarate, α-adipate and branched-chain amino acid-dehydrogenase complexes and the glycine cleavage system, all in the mitochondrial matrix. In these complexes, DLD converts dihydrolipoic acid and NAD+ into lipoic acid and NADH. DLD also has diaphorase activity, being able to catalyze the oxidation of NADH to NAD+ by using different electron acceptors such as O2, labile ferric iron, nitric oxide, and ubiquinone. DLD is thought to have a pro-oxidant role by reducing oxygen to a superoxide or ferric to ferrous iron, which then catalyzes production of hydroxyl radicals. Diaphorase activity of DLD may have an antioxidant role through its ability to scavenge nitric oxide and to reduce ubiquinone to ubiquinol. The dihyrolipamide dehydrogenase gene is known to have multiple splice variants.
Complexes of interacting proteins may also be purified using the SBP-Tag because elution with biotin permits recovery under conditions in which desired complexes remain associated. For example, the Condensin Complex was purified by Kim et al. [2010] and complexes with the TAZ transcriptional co-activator were purified by Zhang et al. [2009]. The SBP-Tag has also been incorporated into several Tandem Affinity Purification (TAP) systems in which successive purification steps are utilized with multiple tags, for example GFP fusion proteins and BTK-protein complexes were purified using a TAP protocol with the SBP-Tag and the His-Tag, HDGF-protein complexes were purified using a TAP protocol with the SBP-Tag and with the FLAG-tag and Wnt complexes were purified using a TAP protocol with the SBP-Tag and with the [Calmodulin-Tag]. TAP is generally used with protein complexes and several studies report significant improvements in purity and yield when the SBP-Tag TAP systems are compared to non-SBP-Tag systems. Commercial TAP systems that use the SBP-Tag include the Interplay® Adenoviral and Mammalian TAP Systems sold by Agilent Technologies, similar products are sold by Sigma-Aldrich.
The marine sulfur cycle is driven by sulfate reduction because hydrogen sulfide is oxidized by microbes for energy or is oxidized abiotically. Dissimilatory sulfate reduction is driven by the degradation of buried organic matter and anaerobic oxidation of methane (AOM) both of which produce carbon dioxide. At depths where sulfate is depleted, methanogenesis is prevalent. At the sulfate-methane transition zone (SMTZ), the upwelling of methane produced by the methanogens is met by the anaerobic methanotrophic archaea in the SMTZ which oxidize it using sulfate as an electron acceptor. More sulfate is present at the SMTZ than methane. A 4:1 ratio of sulfate: methane is observed and the excess sulfate is directed towards organic matter degradation. Syntrophic aggregates of sulfate reducers and methanotrophs have been discovered and the underlying mechanisms observed include direct interspecies electron transfer using large multi heme complexes.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.